02/07/2012 07:35:00

Glaxo, Theravance Get Positive Results From LAMA/LABA (UMEC/VI) in COPD

Related content
09 Jan - 
Adaptimmune confirms GSK Nomination of Second Adaptimmu..
05 Dec - 
Adaptimmune Announces Initiation of Myxoid/Round Cell L..

LONDON--GlaxoSmithKline PLC (GSK.LN) and Theravance, Inc. (THRX) Monday announced positive results from four pivotal phase III studies for once-daily LAMA/LABA (UMEC/VI) in COPD

MAIN FACTS:

-The results of four pivotal phase III studies of investigational LAMA/LABA involving over 4,000 patients with chronic obstructive pulmonary disease.

-These four studies include two 24-week efficacy studies that compared the combination LAMA/LABA, its components and placebo and two 24-week active comparator studies that compared the combination with the LAMA tiotropium, a widely prescribed maintenance bronchodilator for COPD.

-LAMA/LABA is a combination of two investigational bronchodilator molecules - GSK573719 or umeclidinium bromide (UMEC), a long-acting muscarinic antagonist and vilanterol, a long-acting beta2 agonist, administered by a new dry powder inhaler.

-UMEC/VI is a once-daily investigational medicine currently under development for the maintenance treatment of COPD.

-Write to Razak Musah Baba at razak.baba@dowjones.com

(END) Dow Jones Newswires

July 02, 2012 02:35 ET (06:35 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Alliance Trust PLC : Net Asset Value(s)

26/07/2017 12:50:03
ALLIANCE TRUST PLC                                    At the close of business on Tuesday 25 July 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 759.9p -       including income, 768.5p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding income..

Form 8.5 (EPT/RI) - Tesco plc

26/07/2017 09:43:41
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY 1.         KEY INFORMATION (a) Name of exempt principal trader:   Investec Bank plc   (b) Name of offeror/offeree in relation to whose relevant se..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
ATOS : First half 2017 results
2
Columbia University Medical Center’s Center for Biomedical Informatics Collaborates with Admera Health in a Clinical Study, Evaluating Pharmacogenetics in Psychiatric Medications
3
Santen and TRACON Announce Initiation of a Phase 2a Study of DE-122 for the Treatment of Wet Age-Related Macular Degeneration
4
STMicroelectronics Reports 2017 Second Quarter and First Half Financial Results
5
Timberland Bank Reports Growing Profitability for 2017’s Third Fiscal Quarter:

Related stock quotes

Glaxosmithkline PLC ORD .. 1,545.50 -2.6% Stock price decreasing
GlaxoSmithKline PLC 40.95 -2.4% Stock price decreasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
26 July 2017 17:35:46
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170720.2 - EUROWEB6 - 2017-07-26 18:35:46 - 2017-07-26 17:35:46 - 1000 - Website: OKAY